Health authorities in the Democratic Republic of the Congo launched a targeted Ebola vaccination campaign in Kisangani, the capital of Tshopo Province, in an effort to curb the country’s deadliest outbreak of the disease on record. Frontline healthcare workers, emergency response personnel, and individuals who have had direct contact with confirmed cases are being prioritized during the initial phase of the deployment. Health Minister Roger Kamba confirmed that the government initiated the immunization campaign utilizing doses of the Ervebo vaccine to safeguard frontline personnel operating across impacted eastern provinces.

The European Commission has expanded its Ebola response with a €2.1 million purchase of PCR tests for the Bundibugyo virus outbreak. The agreement covers open-platform tests that laboratories can use with existing systems. Shipments are due to start in August as health teams confront a large outbreak centered in the Democratic Republic of the Congo and affecting parts of the wider region.

Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones. Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors. In pre-clinical models, scientists demonstrated that restoring miR-342 levels markedly reduced the spread of cancer cells to distant organs. Furthermore, researchers discovered that palbociclib, an existing CDK4/6 inhibitor drug currently approved for hormone receptor-positive breast cancers, significantly halted metastatic tumor growth in models exhibiting low miR-342 levels. The findings suggest measuring miR-342 levels could allow doctors to repurpose existing therapeutics to treat high-risk patients.

The Democratic Republic of the Congo will receive 70,000 Ervebo Ebola vaccine doses as the Bundibugyo outbreak expands. Congolese authorities reported 5,208 confirmed cases and 2,476 deaths as of Aug. 18. The outbreak now affects 56 health zones across six provinces in the east and northeast. Authorities also listed 1,115 recoveries, while 730 patients remained in isolation or hospital care. The International Coordinating Group on Vaccine Provision approved the release after the government requested doses from the global Ebola stockpile. WHO said 20,000 doses will support a Phase 3 clinical trial focused on Bundibugyo virus disease. The other 50,000 doses will go to frontline and health workers under current vaccination recommendations. WHO and Africa CDC welcomed the allocation, which officials announced on Aug. 20.